Bridgewater Sold Salesforce. Patient Investors Might Want to Buy
Bridgewater Associates sold its stake in Salesforce (CRM), but the article argues this institutional exit could be a buying opportunity for patient investors. Salesforce offers recurring revenue, expanding free cash flow, and a disciplined capital return program—traits long-term holders seek.
Bridgewater Associates, Ray Dalio's hedge fund, recently sold its entire stake in Salesforce (NYSE:CRM), according to a regulatory filing. However, this institutional exit may coincide with an entry point for long-duration investors evaluating durable compounders.
Bridgewater's Rationale
Bridgewater did not disclose the reason for the sale, but it often rebalances based on macroeconomic or valuation factors. The sale could stem from concerns about software spending slowdown or elevated valuations.
Why the Sale Might Be Wrong
Salesforce exhibits characteristics attractive to long-term investors:
- Recurring revenue base: Most revenue comes from subscriptions, providing stability.
- Expanding free cash flow: Improving profit margins and cash generation.
- Disciplined capital return: Share buybacks and dividends.
Context
CRM shares have risen about 15% year-to-date as of the article, but remain below all-time highs. Other analysts maintain buy ratings with an average price target above $350.
What to Make of It
An institutional exit does not necessarily signal a bad stock. Patient investors may find this pullback an opportunity to enter at a better price.
Frequently Asked Questions
Found this useful? Share it